Literature DB >> 21246576

Silicon phthalocyanine (Pc 4) photodynamic therapy is a safe modality for cutaneous neoplasms: results of a phase 1 clinical trial.

Elma D Baron1, Christi L Malbasa, Diana Santo-Domingo, Pingfu Fu, Janine D Miller, Kaija K Hanneman, Andrew H Hsia, Nancy L Oleinick, Valdir C Colussi, Kevin D Cooper.   

Abstract

BACKGROUND: Photodynamic therapy (PDT) is a non-invasive treatment for non-melanoma skin cancer. However, PDT systems currently used clinically have limitations such as pain and superficial tissue penetration. The silicon phthalocyanine Pc 4 is a second-generation photosensitizer with peak absorption in the far red at 675 nm.
OBJECTIVE: To assess the safety and tolerability of topically applied Pc 4 followed by red light (Pc 4-PDT) in treating cutaneous neoplasms. STUDY DESIGN/
MATERIALS AND METHODS: Forty three adults with a diagnosis of neoplasms including actinic keratoses, Bowen's disease, squamous cell carcinoma, basal cell carcinoma, or mycosis fungoides were treated with a single administration of Pc 4-PDT and followed for 14 days. The study utilized a light and Pc 4 dose escalation design in sequential groups of three subjects each.
RESULTS: Pc 4-PDT was well tolerated with no significant local toxicity or increased photosensitivity. It has promising biologic effects, particularly in mycosis fungoides where 14 of 35 subjects demonstrated a clinical response, which correlates with Pc 4-PDT-induced apoptosis, as measured by increased active caspase-3 in the treated skin lesions.
CONCLUSIONS: Pc 4-PDT is a safe and tolerable treatment modality that effectively triggers apoptosis in cutaneous neoplasms such as mycosis fungoides.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21246576      PMCID: PMC3149858          DOI: 10.1002/lsm.20984

Source DB:  PubMed          Journal:  Lasers Surg Med        ISSN: 0196-8092            Impact factor:   4.025


  27 in total

1.  Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality.

Authors:  M A Weinstock; B Gardstein
Journal:  Am J Public Health       Date:  1999-08       Impact factor: 9.308

2.  Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients.

Authors:  H S Zackheim; S Amin; M Kashani-Sabet; A McMillan
Journal:  J Am Acad Dermatol       Date:  1999-03       Impact factor: 11.527

Review 3.  Photodynamic therapy with methylaminolevulinate as a valuable treatment option for unilesional cutaneous T-cell lymphoma.

Authors:  Cristina Zane; Maria Venturini; Raffaella Sala; Piergiacomo Calzavara-Pinton
Journal:  Photodermatol Photoimmunol Photomed       Date:  2006-10       Impact factor: 3.135

4.  Photodynamic therapy with topical 5-aminolevulinic acid for mycosis fungoides: clinical and histological response.

Authors:  D W Edström; A Porwit; A M Ros
Journal:  Acta Derm Venereol       Date:  2001 Jun-Jul       Impact factor: 4.437

5.  Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy.

Authors:  Christiane Querfeld; Steven T Rosen; Timothy M Kuzel; Katharine A Kirby; Henry H Roenigk; Bettina M Prinz; Joan Guitart
Journal:  Arch Dermatol       Date:  2005-03

6.  Pain caused by photodynamic therapy of skin cancer.

Authors:  S Grapengiesser; M Ericson; F Gudmundsson; O Larkö; A Rosén; A-M Wennberg
Journal:  Clin Exp Dermatol       Date:  2002-09       Impact factor: 3.470

7.  Photodynamic therapy of cutaneous lymphoma using 5-aminolevulinic acid topical application.

Authors:  A Orenstein; J Haik; J Tamir; E Winkler; H Trau; Z Malik; G Kostenich
Journal:  Dermatol Surg       Date:  2000-08       Impact factor: 3.398

Review 8.  WHO-EORTC classification for cutaneous lymphomas.

Authors:  Rein Willemze; Elaine S Jaffe; Günter Burg; Lorenzo Cerroni; Emilio Berti; Steven H Swerdlow; Elisabeth Ralfkiaer; Sergio Chimenti; José L Diaz-Perez; Lyn M Duncan; Florent Grange; Nancy Lee Harris; Werner Kempf; Helmut Kerl; Michael Kurrer; Robert Knobler; Nicola Pimpinelli; Christian Sander; Marco Santucci; Wolfram Sterry; Maarten H Vermeer; Janine Wechsler; Sean Whittaker; Chris J L M Meijer
Journal:  Blood       Date:  2005-02-03       Impact factor: 22.113

9.  Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients.

Authors:  H S Zackheim; E H Epstein; W R Crain
Journal:  J Am Acad Dermatol       Date:  1990-05       Impact factor: 11.527

Review 10.  Molecular effectors of multiple cell death pathways initiated by photodynamic therapy.

Authors:  Esther Buytaert; Michael Dewaele; Patrizia Agostinis
Journal:  Biochim Biophys Acta       Date:  2007-07-06
View more
  30 in total

1.  Can nanotechnology potentiate photodynamic therapy?

Authors:  Ying-Ying Huang; Sulbha K Sharma; Tianhong Dai; Hoon Chung; Anastasia Yaroslavsky; Maria Garcia-Diaz; Julie Chang; Long Y Chiang; Michael R Hamblin
Journal:  Nanotechnol Rev       Date:  2012-03       Impact factor: 7.848

2.  C6-pyridinium ceramide sensitizes SCC17B human head and neck squamous cell carcinoma cells to photodynamic therapy.

Authors:  Nithin B Boppana; Ursula Stochaj; Mohamed Kodiha; Alicja Bielawska; Jacek Bielawski; Jason S Pierce; Mladen Korbelik; Duska Separovic
Journal:  J Photochem Photobiol B       Date:  2015-01-10       Impact factor: 6.252

3.  Activated T cells exhibit increased uptake of silicon phthalocyanine Pc 4 and increased susceptibility to Pc 4-photodynamic therapy-mediated cell death.

Authors:  David C Soler; Jennifer Ohtola; Hideaki Sugiyama; Myriam E Rodriguez; Ling Han; Nancy L Oleinick; Minh Lam; Elma D Baron; Kevin D Cooper; Thomas S McCormick
Journal:  Photochem Photobiol Sci       Date:  2016-05-10       Impact factor: 3.982

4.  Synthesis, Photophysical and Photochemical Properties of a Set of Silicon Phthalocyanines Bearing Anti-Inflammatory Groups.

Authors:  Belgin Şahin; Sevinc Zehra Topal; Devrim Atilla
Journal:  J Fluoresc       Date:  2016-11-17       Impact factor: 2.217

5.  Silicon phthalocyanine 4 phototoxicity in Trichophyton rubrum.

Authors:  Minh Lam; Matthew L Dimaano; Patricia Oyetakin-White; Mauricio A Retuerto; Jyotsna Chandra; Pranab K Mukherjee; Mahmoud A Ghannoum; Kevin D Cooper; Elma D Baron
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

6.  Nanoscale Metal-Organic Layer Isolates Phthalocyanines for Efficient Mitochondria-Targeted Photodynamic Therapy.

Authors:  Geoffrey T Nash; Taokun Luo; Guangxu Lan; Kaiyuan Ni; Michael Kaufmann; Wenbin Lin
Journal:  J Am Chem Soc       Date:  2021-02-02       Impact factor: 15.419

Review 7.  On the in vivo photochemical rate parameters for PDT reactive oxygen species modeling.

Authors:  Michele M Kim; Ashwini A Ghogare; Alexander Greer; Timothy C Zhu
Journal:  Phys Med Biol       Date:  2017-02-06       Impact factor: 3.609

8.  Hyaluronic Acid Grafted Nanoparticles of a Platinum(II)-Silicon(IV) Phthalocyanine Conjugate for Tumor and Mitochondria-Targeted Photodynamic Therapy in Red Light.

Authors:  Koushambi Mitra; Montserrat Samso; Charles E Lyons; Matthew C T Hartman
Journal:  J Mater Chem B       Date:  2018-10-24       Impact factor: 6.331

9.  Biodistribution Study of Nanoparticle Encapsulated Photodynamic Therapy Drugs Using Multispectral Imaging.

Authors:  Luma V Halig; Dongsheng Wang; Andrew Y Wang; Zhuo Georgia Chen; Baowei Fei
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2013-03-29

10.  Evaluation of Silicon Phthalocyanine 4 Photodynamic Therapy Against Human Cervical Cancer Cells In Vitro and in Mice.

Authors:  Jill A Gadzinski; Jianxia Guo; Brian J Philips; Per Basse; Ethan K Craig; Lisa Bailey; John T Comerci; Julie L Eiseman
Journal:  Adv Biol Chem       Date:  2016-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.